BSE Live
Mar 27, 15:09Prev. Close
1024.55
Open Price
1019.50
Bid Price (Qty.)
1010.60 (1)
Offer Price (Qty.)
1010.90 (1)
NSE Live
Mar 27, 15:09Prev. Close
1023.50
Open Price
1019.00
Bid Price (Qty.)
1010.30 (235)
Offer Price (Qty.)
1010.50 (71)
| Key Financial Ratios of Laurus Labs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 7.06 | 4.15 | 14.14 | 13.97 | 17.85 | |
| Diluted EPS (Rs.) | 7.05 | 4.15 | 14.09 | 13.97 | 17.77 | |
| Cash EPS (Rs.) | 13.71 | 10.55 | 19.70 | 18.34 | 21.48 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 84.64 | 78.06 | 75.31 | 63.05 | 50.54 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 84.64 | 78.06 | 75.31 | 63.05 | 50.54 | |
| Dividend / Share(Rs.) | 1.20 | 0.80 | 2.00 | 2.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 96.75 | 89.29 | 107.18 | 87.60 | 88.87 | |
| PBDIT/Share (Rs.) | 18.72 | 14.79 | 27.80 | 24.17 | 28.65 | |
| PBIT/Share (Rs.) | 12.07 | 8.39 | 22.22 | 19.79 | 24.98 | |
| PBT/Share (Rs.) | 9.34 | 5.59 | 19.52 | 18.15 | 23.75 | |
| Net Profit/Share (Rs.) | 7.05 | 4.15 | 14.12 | 13.96 | 17.82 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 19.34 | 16.56 | 25.94 | 27.59 | 32.23 | |
| PBIT Margin (%) | 12.47 | 9.39 | 20.73 | 22.58 | 28.11 | |
| PBT Margin (%) | 9.65 | 6.26 | 18.21 | 20.72 | 26.72 | |
| Net Profit Margin (%) | 7.29 | 4.64 | 13.17 | 15.93 | 20.04 | |
| Return on Networth / Equity (%) | 8.33 | 5.31 | 18.74 | 22.13 | 35.25 | |
| Return on Capital Employed (%) | 11.99 | 9.17 | 24.67 | 25.46 | 40.95 | |
| Return on Assets (%) | 4.42 | 2.91 | 10.92 | 11.35 | 16.99 | |
| Total Debt/Equity (X) | 0.51 | 0.49 | 0.41 | 0.48 | 0.46 | |
| Asset Turnover Ratio (%) | 0.64 | 0.66 | 0.85 | 0.77 | 84.77 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.27 | 1.29 | 1.51 | 1.32 | 1.29 | |
| Quick Ratio (X) | 0.72 | 0.67 | 0.76 | 0.62 | 0.64 | |
| Inventory Turnover Ratio (X) | 3.04 | 1.47 | 1.54 | 1.42 | 3.11 | |
| Dividend Payout Ratio (NP) (%) | 11.33 | 38.52 | 14.13 | 11.44 | 7.84 | |
| Dividend Payout Ratio (CP) (%) | 5.83 | 15.15 | 10.12 | 8.71 | 6.50 | |
| Earnings Retention Ratio (%) | 88.67 | 61.48 | 85.87 | 88.56 | 92.16 | |
| Cash Earnings Retention Ratio (%) | 94.17 | 84.85 | 89.88 | 91.29 | 93.50 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 35,373.17 | 23,119.51 | 17,462.13 | 33,285.44 | 20,648.36 | |
| EV/Net Operating Revenue (X) | 6.78 | 4.80 | 3.02 | 7.07 | 4.33 | |
| EV/EBITDA (X) | 35.04 | 29.00 | 11.66 | 25.63 | 13.43 | |
| MarketCap/Net Operating Revenue (X) | 6.34 | 4.39 | 2.73 | 6.74 | 4.07 | |
| Retention Ratios (%) | 88.66 | 61.47 | 85.86 | 88.55 | 92.15 | |
| Price/BV (X) | 7.25 | 5.02 | 3.89 | 9.36 | 7.16 | |
| Price/Net Operating Revenue | 6.34 | 4.39 | 2.73 | 6.74 | 4.07 | |
| Earnings Yield | 0.01 | 0.01 | 0.05 | 0.02 | 0.05 |
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
02.03.2026
26.02.2026
27.01.2026
Laurus Labs Consolidated December 2025 Net Sales at Rs 1,778.29 crore, up 25.67% Y-o-Y
27.01.2026
Laurus Labs Standalone December 2025 Net Sales at Rs 1,509.42 crore, up 19.3% Y-o-Y
28.10.2025
Laurus Labs Consolidated September 2025 Net Sales at Rs 1,653.47 crore, up 35.12% Y-o-Y
27.10.2025
Laurus Labs Standalone September 2025 Net Sales at Rs 1,566.60 crore, up 32.22% Y-o-Y
12.04.2021
Laurus Labs Q4 PAT seen up 366.3% YoY to Rs. 232.2 cr: Sharekhan
18.01.2019
Laurus Labs Q3 PAT may dip 48.3% YoY to Rs. 17.8 cr: Sharekhan
17.10.2018
Laurus Labs Q2 PAT may dip 46.7% YoY to Rs. 30 cr: HDFC Securities
17.10.2018
Laurus Labs Q2 PAT may dip 49.4% YoY to Rs. 24.5 cr: Sharekhan
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
25.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth